Biocartis Group NV: Idylla(TM) MSI Performance Study Selected for Publication at ASCO Conference


You May Also Like

Nabriva Therapeutics Reports Second Quarter 2018 Financial Results and Recent Corporate Highlights

- Company preparing for potential commercialization of two first-in-class antibiotics, Lefamulin (IV and Oral) ...

Aduro Biotech to Host Research and Development Day in New York

BERKELEY, Calif., March 15, 2017 (GLOBE NEWSWIRE) -- Aduro Biotech, Inc. (NASDAQ:ADRO) today announced ...